Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Layla vs Synergy Rx

Two GLP-1 desks, one scoreboard. We put Layla and Synergy Rx head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 125 · Grade C

Layla

Visit Layla Full brief →
vs
No. 145 · Grade C

Synergy Rx

Visit Synergy Rx Full brief →

The verdict

Layla takes this head-to-head.

Layla scores 71 to 67 on our six-factor Brief Score — Layla is a US telehealth weight-loss program built around semaglutide, offering compounded semaglutide as injections and as oral dropper drops, plus compounded tirzepatide and a brand-inclusive GLP-1…

That doesn't make Synergy Rx a bad call — it's best for readers who want to verify who is actually prescribing and compounding their medication, and who will read past the first-month rate to the $249 or $399 they will pay from month two. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
78
54
Supply Reliability
71
82
Transparency
72
60
Access Breadth
62
62
Clinical Oversight
76
84
Track Record
65
66
LaylaBrief Score 71 · 67Synergy Rx

Price, coverage & the tracker

LaylaSynergy Rx
Brief Score71/100 (C)67/100 (C)
SemaglutideFrom $237/mo (all doses, compounded)$249/mo ongoing, compounded ($199 first month only) + an $80 visit fee charged whether or not you get medication
TirzepatideFrom $199/mo (all doses, compounded)$399/mo ongoing, compounded ($349 first month only); the ODT bundles price HIGHER, at $399.67–$399.92/mo
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
On the trackerNewnew to the tracker, no prior readingNewnew to the tracker, no prior reading

Layla: New to the tracker on 1 August 2026. The published line reads From $199/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Synergy Rx: First reading, 7 August 2026. Ongoing month-to-month is $249 semaglutide and $399 tirzepatide; the $199 and $349 figures carried in older datasets are first-month-only rates. An $80 telehealth visit fee sits outside every headline and is charged whether or not medication is dispensed.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.